Iain McGill | BiotechTV

top of page

Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions

Apr 29, 2024

Company News

Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions

Iain McGill discusses the company's clinical liver transplant program, as well as IBD and type 1 diabetes programs.

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Saville's Life Sciences Overview